EUCTR2014-001518-25-DE
Active, not recruiting
Not Applicable
A Phase III, Randomised, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) against Placebo in Subjects with Iron Deficiency Anaemia and who are Intolerant or Unresponsive to Oral Iron Therapy
ConditionsSubjects with iron deficiency anaemia (IDA) caused by different aetiologies such as abnormal uterine bleeding, gastrointestinal diseases (e.g. inflammatory bowel disease), cancer, preoperative anaemia (e.g. orthopaedic surgery), and other conditions leading to IDA and with a documented history of intolerance or unresponsiveness to oral iron therapy.MedDRA version: 17.1Level: PTClassification code 10022972Term: Iron deficiency anaemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Not possible to specify
DrugsMonofer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Subjects with iron deficiency anaemia (IDA) caused by different aetiologies such as abnormal uterine bleeding, gastrointestinal diseases (e.g. inflammatory bowel disease), cancer, preoperative anaemia (e.g. orthopaedic surgery), and other conditions leading to IDA and with a documented history of intolerance or unresponsiveness to oral iron therapy.
- Sponsor
- Pharmacosmos A/S
- Enrollment
- 200
- Status
- Active, not recruiting
- Last Updated
- 10 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •A subject will be eligible for inclusion in the study if he/she fulfils the following criteria:
- •1\. Men or women \= 18 years having IDA caused by different aetiologies\* such as ab\-normal uterine bleeding, gastrointestinal diseases (e.g. inflammatory bowel disease), cancer, preoperative anaemia (e.g. orthopaedic surgery), and other conditions leading to IDA and with a documented history of intolerance or unresponsiveness to oral iron therapy\*\* for at least one month\*\*\* prior to study enrolment
- •2\. Hb \< 11 g/dL
- •3\. TSAT \< 20 %
- •4\. S\-ferritin \< 100 ng/mL
- •5\. Willingness to participate and signing the informed consent form (ICF)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 150
Exclusion Criteria
- •A subject will not be eligible for inclusion in this study if he/she fulfils any of the following criteria:
- •1\. Hb \< 6 g/dL
- •2\. Anaemia predominantly caused by factors other than IDA (e.g. anaemia with untreat\-ed vitamin B12 or folate deficiency, haemolytic anaemia)
- •3\. Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis)
- •4\. Decompensated liver cirrhosis or active hepatitis (ALAT \> 3 times upper limit of normal)
- •5\. Active acute or chronic infections (assessed by clinical judgement supplied with white blood cells (WBC) and C\-reactive protein (CRP))
- •6\. Body weight \< 50 kg
- •7\. Pregnant or nursing women. In order to avoid pregnancy, women of childbearing po\-tential have to use adequate contraception (e.g. intrauterine devices, hormonal contra\-ceptives, or double barrier method) during the whole study period and 7 days after the last dosing
- •8\. History of multiple allergies
- •9\. Known hypersensitivity to parenteral iron or any excipients in the investigational drug products
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of ageEUCTR2013-003535-30-GBGlaxoSmithKline Biologicals1,220
Active, not recruiting
Phase 1
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of ageEUCTR2013-003535-30-DEGlaxoSmithKline Biologicals1,220
Active, not recruiting
Phase 1
A safety and immune study of 2 types of GlaxoSmithKline’s varicella vaccines given as a 2-doses course to healthy children 12-23 months of ageVaccinating Healthy volunteers (Active immunization against varicella virus disease of healthy children in their second year of life).MedDRA version: 18.1Level: PTClassification code 10069613Term: Varicella immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0Level: LLTClassification code 10069628Term: Varicella immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 18.0Level: LLTClassification code 10063315Term: Varicella zoster virus DNA test positiveSystem Organ Class: 100000004848MedDRA version: 18.0Level: LLTClassification code 10046983Term: Varicella zosterSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.1Level: PTClassification code 10046980Term: VaricellaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.0Level: LLTClassification code 10050331Term: Varicella-like rashSystem Organ Class: 100000004858MedDRA version: 18.0Level: LLTClassification code 10063144Term: Varicella zoster virus serology positiveSystem Organ Class: 100000004848Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2013-003535-30-EEGlaxoSmithKline Biologicals1,220
Completed
Phase 3
A study to compare the Efficacy, Safety and Immunogenicity of Sun�s Ranibizumab with Reference Biologic in Patients with Neovascular Age-related Macular degeneration (wet AMD)Health Condition 1: H318- Other specified disorders of choroidCTRI/2020/09/027629Sun Pharmaceutical Industries Limited161
Active, not recruiting
Not Applicable
A Phase III, Randomised, Double-blind, Multi-centre, Withdrawal Study comparing MCI-196 versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (Incorporating a Randomised 12 Week Open-label Dose Titration Period with MCI-196 or Sevelamer)HyperphosphataemiaMedDRA version: 8.1Level: LLTClassification code 10020711Term: HyperphosphataemiaEUCTR2006-003323-37-CZMitsubishi Tanabe Pharma Corporation320